Pentoxifylline Sodium Chloride Injection

By inhibiting phosphodiesterase and activating adenylate cyclase, intracellular cAMP increases, the formation and release of prostaglandins are promoted, the vascular smooth muscle of the arteriolar wall is relaxed, platelet aggregation is inhibited, and partial disaggregation of aggregated platelets is promoted; by increasing the intracellular ATP content, red blood cell stiffness is reduced, and red blood cell deformability is improved; red blood cell aggregation is inhibited; and blood viscosity is reduced, blood flow is promoted, and circulation and nutrition of hypoxic tissues are improved.

Pentoxifylline.

This product is a colorless clear liquid.

1. Cerebral blood circulation disorders such as transient cerebral ischemic attack, sequelae of stroke, and brain dysfunction caused by cerebral ischemia; 2. Peripheral blood circulation disorders such as thromboembolic vasculitis, abdominal artery occlusion, intermittent claudication or rest pain; 3. Inner ear circulation disorders such as sudden deafness, senile tinnitus and deafness; 4. Ocular circulation disorders such as diabetic retinal artery embolism.

Intravenous drip. The patient should be in a supine position during use. The initial dose is 100 mg of pentoxifylline, which is infused within 2-3 hours, and the maximum drip rate should not exceed 100 mg/hour. Depending on the patient's tolerance, the dose can be increased by 50 mg each time, but the dose should not exceed 200 mg each time, 1-2 times a day. The maximum dose should not exceed 400 mg/24 hours.

Gastrointestinal discomfort, such as upper abdominal pressure or fullness, nausea, vomiting, stomach pain, diarrhea, dizziness, headache, may require discontinuation of the drug in individual cases. A few patients may experience irritability and sleep disorders. Reports of flushing, tachycardia, angina pectoris and hypotension are very rare and mostly occur when this product is used in large doses. For such cases, it is usually considered to reduce the daily dose or terminate treatment. Rare skin or systemic allergic reactions, such as itching, rash and angioedema, generally disappear quickly after discontinuation of the drug. Occasionally, there are reports of anaphylactic shock. Thrombocytopenia can be seen in a few patients.

This product is contraindicated for patients who are allergic to pentoxifylline, patients with cerebral hemorrhage and extensive retinal hemorrhage, acute myocardial infarction, pregnant women, severe coronary artery and cerebral vascular sclerosis with hypertension, and severe arrhythmias.

Precautions during pregnancy and lactation: Contraindicated during pregnancy

This product can enhance the effects of antihypertensive drugs, hypoglycemic drugs and anticoagulants.

Keep away from light and store in a sealed container.

250ml: 0.1g pentoxifylline and 2.25g sodium chloride

Cisen Pharmaceutical Co., Ltd.

• Founded in:

  1998-11-06

• Address:

  Tongji Science and Technology Industrial Park, Jining High-tech Zone

• Tax NO.:

  91370800706117999P

• Registered Funds:

  452,754,129 yuan

• Website:

  Log in to view

• Email:

  Log in to view